AKT1 and central nervous system cancer: We conducted an Akt phosphorylation inhibitor treatment assay using MK2206, and found that cell proliferation promoted by PRELID1P6 overexpression was dramatically inhibited by MK2206 in a dose-dependent manner in U138 and LNZ308 glioma cells (Fig. 5C).